Aytu Biopharma (AYTU) Non Operating Income (2010 - 2026)

Aytu Biopharma (AYTU) has 17 years of Non Operating Income data on file, last reported at $149000.0 in Q1 2026.

• Non Operating Income for Q1 2026 came in at $149000.0, up 313.89% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.8 million (up 119.57% YoY), and the FY2025 annual result was -$512000.0, down 158.85% from the prior year.
• Non Operating Income eased to $149000.0 in Q1 2026 per AYTU's latest filing, from $190000.0 in the prior quarter.
• Over five years, Non Operating Income peaked at $3.7 million in Q2 2023 and troughed at -$1.2 million in Q4 2022.
• A 5-year average of $175352.9 and a median of $130000.0 in 2022 frame the typical range for Non Operating Income.
• The sharpest annual moves came in 2023 and 2025: Non Operating Income sank 1034.62% in 2023, then soared 983.33% in 2025.
• A 5-year view of Non Operating Income shows it stood at -$1.2 million in 2022, then surged by 107.82% to $96000.0 in 2023, then surged by 45.83% to $140000.0 in 2024, then soared by 35.71% to $190000.0 in 2025, then retreated by 21.58% to $149000.0 in 2026.
• Business Quant data shows AYTU's Non Operating Income at $149000.0 in Q1 2026, $190000.0 in Q4 2025, and $201000.0 in Q3 2025.